• Explore /
  • Poster
  • / Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).

Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).

Abstract Poster

Authors

null

Aitzaz Qaisar

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Aitzaz Qaisar , Balaji Venugopal , Sonam Ansel , Robert J. Jones , Sarah Slater , Stefan N. Symeonides , Jahangeer Malik , Aravindhan Sundaramurthy , Tony Elliott , Abeera Devasar , Mark Stares , Manreet Randhawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 716)

DOI

10.1200/JCO.2023.41.6_suppl.716

Abstract #

716

Poster Bd #

K11

Abstract Disclosures

Similar Posters

First Author: Jigi Moudgil-Joshi

First Author: Hyejee Ohm

First Author: David Lynn

First Author: Daniel M. Geynisman